Annual Report & AGM Notice

Poolbeg Pharma

12/04/2023 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230412:nRSL8684Va&default-theme=true

RNS Number : 8684V  Poolbeg Pharma PLC  12 April 2023

Poolbeg Pharma plc

 

Annual Report & AGM Notice

 

12 April 2023 - Poolbeg Pharma (http://www.poolbegpharma.com/)  (AIM: POLB,
OTCQB: POLBF, 'Poolbeg' or the 'Company'), a leading biopharmaceutical
company focusing on infectious and prevalent diseases with a high unmet
medical need, confirms that the Company's Annual Report and Accounts for the
period ended 31 December 2022 and the notice of Annual General Meeting
("AGM") 2022 have been posted to shareholders.

 

The 2022 Annual Report and Accounts, the Notice of AGM and accompanying form
of proxy are available to download from the Company's website:
https://www.poolbegpharma.com/investors/documents/
(https://www.poolbegpharma.com/investors/documents/)

 

The Annual General Meeting will be held at the offices of DAC Beachcroft LLP,
25 Walbrook, London EC4N 8AF, United Kingdom on 11 May 2023 at 12pm.

 

- Ends -

 

Enquiries

 Poolbeg Pharma Plc                                                +44 (0) 207 183 1499

 Jeremy Skillington, CEO

 Ian O'Connell, CFO

 finnCap Ltd (Nominated Adviser & Joint Broker)                    +44 (0) 207 220 0500

 Geoff Nash, Charlie Beeson, Nigel Birks, Harriet Ward (ECM)

 Singer Capital Markets (Joint Broker)                              +44 (0) 207 496 3000

 Phil Davies, Sam Butcher

 J&E Davy (Joint Broker)                                           +353 (0) 1 679 6363

 Anthony Farrell, Niall Gilchrist

 Optimum Strategic Communications                                  +44 (0) 208 078 4357

 Mary Clark, Nick Bastin, Vici Rabbetts                            poolbeg@optimumcomms.com (mailto:poolbeg@optimumcomms.com)

 

About Poolbeg Pharma

 

Poolbeg Pharma specialises in the development of innovative medicines to
address the unmet need in infectious and other prevalent diseases. Poolbeg has
a disciplined portfolio approach to mitigate risk, accelerate drug
development, and enhance investor returns. The Company simultaneously advances
multiple programmes in cost-effective clinical trials, rapidly generating
early human safety and efficacy data to enable early partnering /
out-licensing, with the funds generated reinvested in the pipeline. Poolbeg
also uses AI to interrogate human challenge trial data sets to quickly
identify new targets and drugs, and in-license near or in the clinic
medicines, leading to faster development and greater commercial appeal.

 

The Company is targeting the growing infectious disease market. In the wake of
the COVID-19 pandemic, infectious disease has become one of the fastest
growing pharma markets and is expected to exceed $250bn by 2025. Through
opportunistic identification of assets which complement Poolbeg's existing
pipeline, the Company is progressing programmes in oncology and metabolic
syndromes; adding disease areas with significant addressable markets.

 

With its initial assets from hVIVO plc (http://www.hvivo.com/)
 (formerly Open Orphan plc), an industry leading infectious disease and
human challenge trials business, Poolbeg has access to knowledge, experience,
and clinical data from over 20 years of human challenge trials. The Company is
using these insights to acquire new assets as well as reposition clinical
stage products, reducing spend and risk. Amongst its portfolio of exciting
assets, Poolbeg has a small molecule immunomodulator for severe influenza and
other acute inflammatory conditions (POLB 001) which produces a highly
significant reduction in p38 MAP kinase driven cytokines in a clinical
setting; a first-in-class, intranasally administered RNA-based immunotherapy
for respiratory virus infections (POLB 002); and a vaccine candidate for
Melioidosis (POLB 003). The Company is also developing
two Oral Delivery Programmes and is progressing
two Artificial Intelligence (AI) Programmes to add promising new assets to
its pipeline.

 

For more information, please go to www.poolbegpharma.com
(http://www.poolbegpharma.com/)  or follow us on Twitter
(https://twitter.com/PoolbegPharma)  and LinkedIn
(https://www.linkedin.com/company/poolbeg-pharma/)  @PoolbegPharma.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NOAFLFFESIILLIV